Nimedine (Cilastatin, Imipenem)

Imipenem/cilastatin, the active ingredient in Nimedine, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, lower respiratory tract infections, skin and soft‑tissue infections, and septicemia in hospitalized patients.

GNH USA supplies Nimedine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nimedine (imipenem/cilastatin) is employed for serious bacterial infections that require broad‑spectrum intravenous therapy.

- Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: clears resistant Gram‑negative organisms. - Lower respiratory tract infections (including pneumonia): provides rapid bacterial kill in lung tissue. - Skin and soft‑tissue infections: treats severe cellulitis and necrotizing infections. - Septicemia and other severe bacterial infections: offers systemic coverage for life‑threatening sepsis.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in transaminases. - Infusion site reactions: redness or discomfort at the injection site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Severe neutropenia: marked reduction in white blood cells. - Acute renal failure: sudden loss of kidney function. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions.

Before initiating therapy, consider the following precautions: - Renal function monitoring: adjust dose in patients with impaired kidney function. - Allergy assessment: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: use cautiously in patients with a history of seizures or CNS disorders. - Drug interactions: review concomitant medications that may affect renal clearance. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin may interact with several medicines.

Major Interactions (Avoid): - Valproic acid: reduces serum valproate levels, risking seizure breakthrough. - Cimetidine: may increase imipenem concentrations, heightening toxicity. - Probenecid: can raise renal tubular concentrations, increasing nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: additive risk of renal impairment. - Aminoglycosides: potential for enhanced nephrotoxicity. - Anticoagulants (e.g., warfarin): monitor INR for possible alterations.